

State of the TB Alliance

Mel Spigelman

President and CEO

TB Alliance

Putting science to work for better, faster TB cures

A nonprofit Product Development Partnership dedicated to the discovery, development, and delivery of improved TB therapeutics that reach all who need them

- **Revolutionized** treatment for highly drug-resistant TB
- **Markedly improved** treatments for children with DS-TB
- **Transformed** how TB treatments are developed
- **Revived** the pipeline for new TB drugs
- **Mobilized** a global network of partners



The Future of TB Treatment

Discover, develop, and deliver better and faster TB treatments

Our Vision

To treat latent TB infections in
one day


To treat active TB infections in
one month



Achieving our vision will require:

- A sustainable pipeline of highly effective and safe novel therapeutics
- Leveraging advances in formulation science and much greater understanding of host responses to *M.tb*
- All TB treatments available for special populations such as children

TB Alliance **collaborates with more than 350 partners** around the world.



More than
60
academic partners across
19 countries

More than
100
public-sector partners across
35+ countries

More than
130
private-sector partners
across **25 countries**

More than
40
civil society organizations and
Community Advocacy Boards
across **46 countries**

Strategic Review Process

In response to a rapidly evolving external and internal environment, TB Alliance is carrying out a strategic review which will:

- Ensure that TB Alliance can continue to respond to new challenges
- Through a participatory process involving internal and external TB Alliance stakeholders, refine and articulate our strategic vision and mission
- Identify priority areas for engagement
- The result will be an even more effective, sustainable and relevant organization positioned to significantly contribute to marked improvements in global health

Strategic Pillars: Discovery, Development & Delivery

Putting science to work for better, faster TB cures

Discover

Active and **latent** TB

- Conventional small molecules
- **Immunotherapies**
- **Artificial intelligence**
- **Long-acting injectables**

Develop

Expanded participation in
multilateral **consortia**

- Novel clinical development
- Universal regimens
- Special populations

Deliver

Adoptable, Affordable and
Available

- Multiple novel partnerships
- **Enhanced market and feasibility studies**
- Technical assistance
- **Increased diagnosis and treatment**

Addressing Unmet Needs in NTMs

TB Alliance Donors

